This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2015 Mar 7;385(9971):832-4.

doi: 10.1016/S0140-6736(15)60212-4. Epub 2015 Feb 13.

Dual anti-inflammatory agents prevent COPD exacerbations

Donald P Tashkin¹

Affiliations

PMID: 25684589
DOI: 10.1016/S0140-6736(15)60212-4

Comment

Dual anti-inflammatory agents prevent COPD exacerbations

Donald P Tashkin. Lancet. 2015.

. 2015 Mar 7;385(9971):832-4.

doi: 10.1016/S0140-6736(15)60212-4. Epub 2015 Feb 13.

Author

Donald P Tashkin¹

Affiliation

¹ Division of Pulmonary and Critical Care Medicine, David Geffen School of Medicine, Los Angeles, CA 90095, USA. Electronic address: dtashkin@mednet.ucla.edu.

PMID: 25684589
DOI: 10.1016/S0140-6736(15)60212-4

No abstract available

PubMed Disclaimer

Comment on

Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial.
Martinez FJ, Calverley PM, Goehring UM, Brose M, Fabbri LM, Rabe KF. Martinez FJ, et al. Lancet. 2015 Mar 7;385(9971):857-66. doi: 10.1016/S0140-6736(14)62410-7. Epub 2015 Feb 13. Lancet. 2015. PMID: 25684586 Clinical Trial.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Medical
- MedlinePlus Health Information